About Us

OptoQuest

Mission

OptoQuest aims to break the barriers to the optimal practice of corneal and refractive surgery. We believe that helping ophthalmic practices utilize principles of risk-mitigation and data-driven engineering will enable them to maximize safety, outcomes, and economics for both patients and practitioners.

cleclinicinn.jpg
oh3f.png
rpb.jpg

OptoQuest is the culmination of years of research and development in computational modeling and non-invasive, biomechanical measurement of the eye, and is positioned to lead the simulation-based medicine revolution in anterior segment surgery.

OptoQuest’s commercialization efforts are supported in part by an Innovation Platform Award from the Ohio Third Frontier Commission (Award 13-059) and by Cleveland Clinic Innovations. Scientific support has been provided by the National Institutes of Health (through a National Eye Institute Bioengineering Research Grant (R01 EY023381) and an NIH Roadmap Multidisciplinary Clinical Research Career Development Programs Grant (K12RR023264/1KL2RR024990)), Research to Prevent Blindness (through a Career Development Award to Dr. Dupps and an Unrestricted Grant to the Department of Ophthalmology of the Cleveland Clinic Lerner College of Medicine of CWRU) and the National Keratoconus Foundation/Discovery Eye Foundation.

BJ Dupps

William J. Dupps Jr., MD, PhD

Founder

Dr. Dupps is a native of Catawba Island, Ohio, and is a leader in the field of ocular biomechanics. He joined the staff of the Cleveland Clinic in 2006, with appointments in Ophthalmology, Biomedical Engineering and Transplantation, and holds adjunct appointments in Biomedical Engineering at Case Western Reserve University and Cleveland State University.

After graduating with an undergraduate degree in Chemical Engineering from Purdue University, he completed his master’s and doctoral degrees in Biomedical Engineering at The Ohio State University, where he also earned his medical degree with honors in the Medical Scientist Training Program. He completed an ophthalmology residency at the University of Iowa, and a two-year Cornea and Refractive Surgery Fellowship at the Cole Eye Institute.

Dr. Dupps was a Scholar in the NIH Multidisciplinary Clinical Research Training Program and has received continuous research support for his work on corneal biomechanical measurement and patient-specific modeling through the National Eye Institute, a Research to Prevent Blindness Career Development Award, and an Ohio Third Frontier Innovation Platform Award. He has been Associate Editor for the Journal of Refractive Surgery since 2007, and Executive Editor of Experimental Eye Research since 2013.

Dr. Dupps is a recipient of a Distinguished Alumnus Award from The Ohio State University College of Engineering, an Achievement Award from the American Academy of Ophthalmology, and was the first recipient of Cleveland Clinic’s Early Career Innovation Award for founding OptoQuest in 2008.

Josh Lloyd

Josh Lloyd

Director of Operations

Josh has nearly a decade of experience in management of small and start-up business with 4+ years in the medical device space. He has straddled both research and management functions within various companies and start-up teams. His academic and professional expertise has been in identifying, validating, marketing, and executing on technology-based business opportunities, but has also successfully managed every conceivable aspect of operations including product management, quality assurance among other functions. Josh received a Masters Degree in Entrepreneurial Biotechnology from Case Western Reserve University. He also is one of the distinguished Crocker Innovation Fellows from Brigham Young University.

Ibrahim Seven

Ibrahim Seven, PhD

Director of Research and Development

Bio coming soon.

David Bragg

David Bragg

Board Member

David is a 30 year veteran of the ophthalmic and medical device industries. Currently he serves as President of Ziemer USA and Canada. Under his leadership Ziemer has become one of the largest market share providers in the Lasik business segment. He has also expanded the company’s market segments to include Cataract and Presbyopia.

He served as Vice President of Business Development at TrueVision from 2005-2007 where he was responsible for worldwide market introduction of 3D technology for surgical applications in Neuro, Spine, ENT and Ophthalmology. David was recruited by Versant Ventures in 2005 to start WaveTec. In his role he was responsible for product development, early stage market adoption and fundraising. In 2014 WaveTec was acquired by Alcon Surgical a Novartis Company. In 1999 he was recruited to the position of Vice President, Global Sales and Marketing for Advanced Vision Science (AVS). In this role he was responsible for the restructuring of the global sales and marketing organization. David has also held various executive positions with Bausch and Lomb, Chiron Vision and Johnson and Johnson.

David received a BA degree in Economics from the University of Minnesota.

David Eichler

David Eichler

Board Member

As a Partner with Cleveland Clinic Ventures, Dave brings over 20 years of experience as a venture investor, board member, and advisor to healthcare entrepreneurs. Dave’s areas of focus include Health IT and IT-Enabled Medical Device opportunities.

Prior to joining Cleveland Clinic Ventures, Dave was a Managing Partner at Psilos Group Managers, a leading healthcare investment firm with approximately $600 million under management. He has a successful track record of venture and growth equity stage investments in Health IT, healthcare services, and medical technology companies -- including extensive Board level experience with value-added engagement in the areas of strategy, business growth, product development, sales improvement, organizational development, capital formation and M&A/exits. In addition to his investing roles, Dave’s background includes various senior operating roles at Caregiver Services, Inc. (a Psilos portfolio company) during periods of transformational growth at the company. Earlier in his career, Dave was an investment banker at Wasserstein Perella & Co. as a member of the firm’s Healthcare Group. Dave earned an MBA from the Darden School of Business at the University of Virginia, where he received the faculty award for academic excellence (top 10% of class). He holds another masters degree in National Security Studies from Georgetown University and a B.A. in Government and International Relations from Cornell University, where he graduated magna cum laude.

Sonja O'Malley

Sonja O'Malley

Board Member

Sonja O'Malley has over 20 years of experience in healthcare information technology. Prior to joining CCI, Sonja was responsible for managing the global life sciences client portfolio at Axentis. Axentis, a Wolters Kluwer business, is a software provider of on-demand solutions used by life science customers and other highly regulated industries to minimize their exposure to risk and optimize business performance; a $5 billion (2010) company with 19,000 employees worldwide. Sonja's work has spanned clinical laboratory medicine as a MT (ASCP), consulting in the health care practice of Andersen Consulting, directing the process improvement practice within a health insurance organization, and building multiple startups as an early employee.

Sonja is a certified PMP from the Project Management Institute and has a BS in medical technology from Miami University and an MBA from the Weatherhead School of Management at Case Western Reserve University.